Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
	4610	57-50-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: sucrose cane sugar saccharose D-Sucrose	A nonreducing disaccharide composed of GLUCOSE and FRUCTOSE linked via their anomeric carbons. It is obtained commercially from SUGARCANE, sugar beet (BETA VULGARIS), and other plants and used extensively as a food and a sweetener. Molecular weight: 342.30 Formula: C12H22O11 CLOGP: -3.09 LIPINSKI: 2 HAC: 11 HDO: 8 TPSA: 189.53 ALOGS: 0.38 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

sucrose
cane sugar
saccharose
D-Sucrose

A nonreducing disaccharide composed of GLUCOSE and FRUCTOSE linked via their anomeric carbons. It is obtained commercially from SUGARCANE, sugar beet (BETA VULGARIS), and other plants and used extensively as a food and a sweetener.

Molecular weight: 342.30
Formula: C12H22O11
CLOGP: -3.09
LIPINSKI: 2
HAC: 11
HDO: 8
TPSA: 189.53
ALOGS: 0.38
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK2,PDK4,PIK3CD,PRKDC,SIK2,STK33,TEK	25
kinase-selectivity-class	ACVRL1,AXL,CDK1,CDK2,CDK4,CHUK,IRAK4,MAP2K6,MAP3K14,PDK1,PIK3CD,ZAP70	12
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product dose omission issue	29.13	21.21	37	2342	291650	90334418

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	172.89	30.67	58	3466	13398	42604413
Appendicitis	152.29	30.67	59	3465	20554	42597257
Blood phosphorus increased	122.26	30.67	44	3480	12481	42605330
Ventricular fibrillation	121.22	30.67	56	3468	30067	42587744
Cardiogenic shock	109.30	30.67	55	3469	35585	42582226
Myasthenia gravis	107.91	30.67	43	3481	16094	42601717
Abdominal distension	104.35	30.67	68	3456	71667	42546144
Ascites	100.68	30.67	61	3463	56617	42561194
Blood uric acid increased	99.01	30.67	40	3484	15507	42602304
Stress	98.14	30.67	55	3469	44157	42573654
Dry mouth	92.30	30.67	51	3473	39828	42577983
Blood cholesterol increased	75.34	30.67	39	3485	26702	42591109
Hyperphosphataemia	71.06	30.67	30	3494	12974	42604837
Incorrect route of product administration	64.32	30.67	34	3490	24271	42593540
Multiple organ dysfunction syndrome	63.13	30.67	57	3467	96978	42520833
Abdominal pain	63.10	30.67	78	3446	190393	42427418
Hyponatraemia	62.89	30.67	58	3466	101404	42516407
Neuralgia	59.84	30.67	33	3491	25614	42592197
Constipation	54.57	30.67	67	3457	162224	42455587
Hypophosphataemia	54.56	30.67	29	3495	20916	42596895
General physical health deterioration	51.74	30.67	63	3461	151183	42466628
Swelling	45.33	30.67	37	3487	54848	42562963
Bacteroides infection	44.78	30.67	14	3510	2573	42615238
Sleep disorder therapy	44.76	30.67	18	3506	6876	42610935
Bacterial infection	44.32	30.67	28	3496	27851	42589960
Sleep disorder	43.07	30.67	34	3490	48061	42569750
Analgesic therapy	42.24	30.67	17	3507	6507	42611304
Somnolence	39.13	30.67	53	3471	141052	42476759
Aortic stenosis	37.44	30.67	17	3507	8728	42609083
Total lung capacity decreased	36.53	30.67	13	3511	3557	42614254
Diabetes mellitus	36.48	30.67	34	3490	60053	42557758
Thrombosis	36.37	30.67	36	3488	68475	42549336
Drug therapy	35.77	30.67	15	3509	6365	42611446
Chronic obstructive pulmonary disease	33.19	30.67	33	3491	63081	42554730
Activated partial thromboplastin time prolonged	33.10	30.67	19	3505	15884	42601927
Ulcer	32.52	30.67	19	3505	16422	42601389
Intentional product misuse	31.88	30.67	32	3492	61868	42555943

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Appendicolith	199.11	21.76	58	5381	14197	110569663
Appendicitis	163.43	21.76	59	5380	28405	110555455
Ventricular fibrillation	132.02	21.76	56	5383	41257	110542603
Blood phosphorus increased	129.10	21.76	43	5396	16297	110567563
Myasthenia gravis	121.25	21.76	44	5395	21467	110562393
Cardiogenic shock	111.45	21.76	55	5384	57283	110526577
Blood uric acid increased	106.47	21.76	40	5399	21489	110562371
Abdominal distension	100.73	21.76	77	5362	175026	110408834
Ascites	99.41	21.76	60	5379	92748	110491112
Stress	92.42	21.76	60	5379	105288	110478572
Hyperphosphataemia	79.40	21.76	30	5409	16351	110567509
Neuralgia	69.71	21.76	38	5401	48440	110535420
Multiple organ dysfunction syndrome	66.59	21.76	57	5382	151653	110432207
Abdominal pain	59.34	21.76	97	5342	512892	110070968
Constipation	59.10	21.76	80	5359	357706	110226154
Hypophosphataemia	56.15	21.76	29	5410	33153	110550707
Incorrect route of product administration	54.94	21.76	36	5403	64025	110519835
Sleep disorder therapy	52.44	21.76	18	5421	7453	110576407
Dry mouth	51.44	21.76	56	5383	199892	110383968
Hyponatraemia	50.92	21.76	58	5381	217595	110366265
Bacteroides infection	50.28	21.76	14	5425	2905	110580955
Analgesic therapy	49	21.76	17	5422	7267	110576593
Thrombosis	48.00	21.76	41	5398	108621	110475239
Bacterial infection	47.28	21.76	29	5410	46007	110537853
Drug therapy	41.38	21.76	15	5424	7276	110576584
Diabetes mellitus	40.86	21.76	36	5403	99345	110484515
Aortic stenosis	39.36	21.76	17	5422	13042	110570818
Activated partial thromboplastin time prolonged	39.14	21.76	20	5419	22348	110561512
Chronic obstructive pulmonary disease	37.96	21.76	36	5403	109122	110474738
Somnolence	35.32	21.76	57	5382	297392	110286468
Sepsis	35.21	21.76	60	5379	327286	110256574
Total lung capacity decreased	34.36	21.76	13	5426	7101	110576759
End stage renal disease	31.32	21.76	17	5422	21456	110562404
Therapeutic reaction time decreased	30.48	21.76	11	5428	5268	110578592
Intentional product misuse	28.67	21.76	34	5405	132870	110450990
General physical health deterioration	28.66	21.76	64	5375	425231	110158629
Gout	27.62	21.76	19	5420	36547	110547313
Blood cholesterol increased	26.98	21.76	39	5400	184746	110399114
Anticoagulant therapy	26.63	21.76	10	5429	5351	110578509
Antacid therapy	26.41	21.76	10	5429	5474	110578386
Blood calcium increased	25.53	21.76	14	5425	18026	110565834
Testicular haemorrhage	25.00	21.76	5	5434	248	110583612
Sleep disorder	24.84	21.76	39	5400	198605	110385255
Ulcer	24.81	21.76	19	5420	43097	110540763
Troponin increased	23.75	21.76	16	5423	29750	110554110
Off label use	22.58	21.76	138	5301	1500047	109083813
Lung opacity	22.08	21.76	11	5428	11641	110572219

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D005421	Flavoring Agents
MeSH PA	D005503	Food Additives
MeSH PA	D013549	Sweetening Agents
CHEBI has role	CHEBI:25728	osmolyte
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:50505	sweetening agent
CHEBI has role	CHEBI:75771	mouse metabolite
CHEBI has role	CHEBI:75772	<em>Saccharomyces cerevisiae </em> metabolite
CHEBI has role	CHEBI:76971	<em>Escherichia coli</em> metabolite
CHEBI has role	CHEBI:77746	human metabolite
CHEBI has role	CHEBI:84735	algal metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.07	acidic
pKa2	13.11	acidic
pKa3	13.8	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D00025	KEGG_DRUG
4019358	VUID
N0000147528	NUI
4019358	VANDF
CHEBI:17992	CHEBI
SUC	PDB_CHEM_ID
CHEMBL253582	ChEMBL_ID
5411	IUPHAR_LIGAND_ID
DB02772	DRUGBANK_ID
C151H8M554	UNII
10159	RXNORM
NOCODE	MMSL
002598	NDDF
11320009	SNOMEDCT_US
9745007	SNOMEDCT_US
C0038636	UMLSCUI
D013395	MESH_DESCRIPTOR_UI
5988	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Select Brand Anti-Nausea	HUMAN OTC DRUG LABEL	2	15127-291	SOLUTION	3.74 g	ORAL	unapproved drug other	11 sections
Emetrol Cherry	HUMAN OTC DRUG LABEL	2	68788-9801	SOLUTION	3.74 g	ORAL	Unapproved drug other	13 sections
GZE GODDESS SUGAR SCRUB	HUMAN OTC DRUG LABEL	1	74458-216	CAPSULE	15 g	TOPICAL	OTC Monograph Drug	10 sections
GZE GODDESS SUGAR SCRUB	HUMAN OTC DRUG LABEL	1	74458-217	GRANULE	15 g	TOPICAL	OTC Monograph Drug	10 sections
AOAO Kojic Acid Whitening Lightener	HUMAN OTC DRUG LABEL	6	84509-035	SOAP	1600 mg	TOPICAL	OTC Monograph Drug	9 sections
AOAO Kojic Acid Whitening Lightener	HUMAN OTC DRUG LABEL	6	84509-049	SOAP	1600 mg	TOPICAL	OTC Monograph Drug	9 sections

Ask DrugCentral

Try a sample question

sucrose 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: